Biocon’s partner Mylan, has entered into an in-licensing deal to speed up commercialization of biosimilar Humira, developed by Fujifilm Kyowa Kirin Biologics for European markets.
Adalimumab the biosimilar of Humira is suggested for patients suffering from various autoimmune disorders. As per the terms of agreement, Fujifilm grants Mylan an exclusive license to commercialize the Adalimumab biosimilar in Europe and will receive an up-front fee. In return, Fujifilm is eligible to receive a subsequent commercialization milestone payment and sales royalties.
Moreover the company’s spokesperson stated, “We believe that through this arrangement, Mylan could commercialize FKB’s Adalimumab in EU around market formation. Biocon retains its economic interest in this arrangement vis-a-vis Mylan in line with its existing global collaboration with Mylan for monoclonal antibodies.”
